Meet the Venture Capital Panel

SEBIO 2019 > News > Meet the Venture Capital Panel

Meet the Venture Capital Panel

November 6, 2017 | News

Venture capital continues to play a critical role in financing innovation in the life sciences. The Southeast BIO Investor and Partnering Forum will feature a panel of prominent industry investors on November 16, 2017 in Pinehurst, NC. The panel will focus on current trends, including the unprecedented amount of capital currently flowing into the industry and the state of the public markets. The following individuals will be featured.

Peter Kolchinsky is a founder, Portfolio Manager, and Managing Director at RA Capital Management. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a Board Member for various public and privately held companies, including Dicerna Pharmaceuticals, Inc. and Wave Life Sciences Ltd. Peter also leads the firm’s outreach and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policy makers, and industry.  He authored “The Entrepreneur’s Guide to a Biotech Startup” and served on the Board of Global Science and Technology for the National Academy of Sciences. Peter holds a BS from Cornell University and a PhD in Virology from Harvard University.

Josh Resnick co-leads SV’s US Biotech practice out of SV’s Boston office. He is also responsible for SV’s venture-creation activities, including the activities of SV’s incubator, Brahma Discovery. He is a member of the investment committee of the Dementia Discovery Fund. Josh is a highly-regarded life science venture capital leader, entrepreneur, and investment professional with more than 15 years of experience in investing, company formation, and company leadership across all stages from discovery through commercialization.  Before joining SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund that he built and managed within Merck & Co. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture, focusing on company formation, seed and Series A investing. During his tenure at Atlas, Josh was also the Founder and CEO of startups in the immune-oncology and neuro spaces. Prior to Atlas Venture, he was a Partner at Prism Venture Partners. Earlier, Josh founded or co-founded companies in the med tech and digital health spaces.

The panel will be moderated by Clay Thorpe who is an entrepreneur turned venture capitalist. Since 1995, Clay has co-founded eight companies in the life science arena and co-founded Hatteras in 2000. Since co-founding Hatteras, Clay has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $450 million across five venture funds. Clay has led investments in a range of life science companies, including biopharmaceutical, medical device, diagnostics, and research informatics.  Clay has led investments and numerous strategic transaction processes in a variety of portfolio companies, including PhaseBio, ArtusLabs, Clearside Biomedical, Synthematix, Embrella, Asthmatx, Lysosomal Therapeutics, Inc., and others. In operating roles, Clay was a co-founder and served as CEO and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired in April 2005 by Symyx Technologies (SMMX). He was the co-founder and head of corporate development for Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon’s sale to Karo Bio for $106.7 million in May of 2000. Prior to Novalon, Clay was the co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins.